All In Biotech

Drug Trial Radar · NCT06521255

Evaluate the Safety and Efficacy of Tafasitamab and Lenalidomide in Combination With Gemcitabine and Oxaliplatin Versus Rituximab in Combination With Gemcitabine and Oxaliplatin in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma

A Randomized, Multi-center, Phase 3 Study of Tafasitamab and Lenalidomide in Combination With Gemcitabine and Oxaliplatin Versus Rituximab in Combination With Gemcitabine and Oxaliplatin in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Last checked: Nov 20, 2026Latest source record: Jul 25, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 244 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

244

Planned (sponsor's estimate)

Start

May 7, 2024

Primary completion

Sep 2028

Study completion Dec 2029

Sponsor

Sponsor type
Industry
First posted
Jul 25, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a Randomized, Multi-center, Phase 3 Study of Tafasitamab and Lenalidomide in Combination with Gemcitabine and Oxaliplatin versus Rituximab in Combination with Gemcitabine and Oxaliplatin in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphom

Conditions

  • DLBCL

Interventions

  • TafasitamabDrug

    Tafasitmab was infused intravenously

  • LenalidomideDrug

    Lenalidomide orally

  • GemcitabineDrug

    Gemcitabine was infused intravenously

  • OxaliplatinDrug

    Oxaliplatin was infused intravenously

  • RituximabDrug

    Rituximab was infused intravenously.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Dose limiting toxicity(DLT)and other adverse events (AEs) of tafasitamab and lenalidomide in combination with GemOx (TL-GemOx) assessed using CTCAE v5.0Time frame: within 28 days after therapy initiation
  2. PFS assessed by IRC according to Lugano 2014Time frame: 1-3 years approximately

Locations

20 sites in 1 country. Site status is shown where the registry gives one.

  • Beijing Hospital

    Beijing, China · Not yet recruiting

  • The First Hospital Of Jilin University

    Changchun, China · Not yet recruiting

  • Hunan Cancer Hospital

    Changsha, China · Not yet recruiting

  • Chenzhou No.1 People's Hospital

    Chaozhou, China · Not yet recruiting

  • Sichuan Province People's Hospital

    Chengdu, China · Recruiting

  • The First Affiliated Hospital of Chongqing Medical University

    Chongqing, China · Not yet recruiting

  • Guangdong General Hospital

    Guangzhou, China · Not yet recruiting

  • Sun Yat-sen University Cancer Center

    Guangzhou, China · Recruiting

  • Hangzhou First People's Hospital

    Hangzhou, China · Not yet recruiting

  • The First Affiliated Hospital, Zhejiang University School of Medicine

    Hangzhou, China · Not yet recruiting

  • Shandong Cancer Hospital and Institute

    Jinan, China · Not yet recruiting

  • Jiangxi Cancer Hospital

    Nanchang, China · Not yet recruiting

  • The First Affiliated Hospital of Nanchang University

    Nanjing, China · Not yet recruiting

  • Ruijin Hospital Shanghai Jiaotong University School of Medicine

    Shanghai, China · Not yet recruiting

  • The Second Affiliated Hospital of Soochow University

    Suzhou, China · Recruiting

  • Tianjin First Central Hospital

    Tianjin, China · Not yet recruiting

  • Xinjiang Medical University Affiliated Cancer Hospital

    Ürümqi, China · Not yet recruiting

  • The First Affiliated Hospital Wenzhou Medical University

    Wenzhou, China · Not yet recruiting

  • Union Hospital Tongji Medical College

    Wuhan, China · Not yet recruiting

  • Henan Cancer Hospital

    Zhengzhou, China · Not yet recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.